Improving Enrollment For Challenging Protocol

A biopharma company developed an ingestible powder composed of non-digestible oligosaccharides specifically for patients with ulcerative colitis (UC), with a goal of positively affecting their gut microbiomes. The study needed to enroll 30 subjects with mild to moderate UC symptoms both domestically and abroad. Elligo was brought on to assist with enrolling 20 subjects in the U.S. 

Find out the challenges and solutions in the available case study.